Legend Biotech Corporation Statistics
Share Statistics
Legend Biotech Corporation has 183.45M shares outstanding. The number of shares has increased by 0.48% in one year.
| Shares Outstanding | 183.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 181.93M |
| Failed to Deliver (FTD) Shares | 33 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 15.86M, so 8.64% of the outstanding shares have been sold short.
| Short Interest | 15.86M |
| Short % of Shares Out | 8.64% |
| Short % of Float | 8.72% |
| Short Ratio (days to cover) | 12.18 |
Valuation Ratios
The PE ratio is -20.44 and the forward PE ratio is -59.97.
| PE Ratio | -20.44 |
| Forward PE | -59.97 |
| PS Ratio | 37.16 |
| Forward PS | 6.3 |
| PB Ratio | 8.47 |
| P/FCF Ratio | -25.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Legend Biotech Corporation has an Enterprise Value (EV) of 9.65B.
| EV / Earnings | -18.61 |
| EV / Sales | 33.83 |
| EV / EBITDA | -20.18 |
| EV / EBIT | -21.95 |
| EV / FCF | -23.19 |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.92 |
| Quick Ratio | 6.83 |
| Debt / Equity | 0.22 |
| Total Debt / Capitalization | 18.36 |
| Cash Flow / Debt | -1.4 |
| Interest Coverage | -20.17 |
Financial Efficiency
Return on equity (ROE) is -0.41% and return on capital (ROIC) is -27.72%.
| Return on Equity (ROE) | -0.41% |
| Return on Assets (ROA) | -0.28% |
| Return on Capital (ROIC) | -27.72% |
| Revenue Per Employee | 118.81K |
| Profits Per Employee | -215.94K |
| Employee Count | 2.40K |
| Asset Turnover | 0.15 |
| Inventory Turnover | 7.42 |
Taxes
| Income Tax | -1.86M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -42.58% in the last 52 weeks. The beta is 0.11, so Legend Biotech Corporation's price volatility has been higher than the market average.
| Beta | 0.11 |
| 52-Week Price Change | -42.58% |
| 50-Day Moving Average | 43.05 |
| 200-Day Moving Average | 49.36 |
| Relative Strength Index (RSI) | 29.52 |
| Average Volume (20 Days) | 1.42M |
Income Statement
In the last 12 months, Legend Biotech Corporation had revenue of $285.14M and earned -$518.25M in profits. Earnings per share was $-2.94.
| Revenue | 285.14M |
| Gross Profit | 140.93M |
| Operating Income | -439.49M |
| Net Income | -518.25M |
| EBITDA | -477.87M |
| EBIT | -439.49M |
| Earnings Per Share (EPS) | -2.94 |
Balance Sheet
The company has $1.28B in cash and $328.67M in debt, giving a net cash position of $949.04M.
| Cash & Cash Equivalents | 1.28B |
| Total Debt | 328.67M |
| Net Cash | 949.04M |
| Retained Earnings | -1.48B |
| Total Assets | 1.74B |
| Working Capital | 1.08B |
Cash Flow
In the last 12 months, operating cash flow was -$393.28M and capital expenditures -$22.72M, giving a free cash flow of -$416.00M.
| Operating Cash Flow | -393.28M |
| Capital Expenditures | -22.72M |
| Free Cash Flow | -416.00M |
| FCF Per Share | -2.36 |
Margins
Gross margin is 49.42%, with operating and profit margins of -154.13% and -181.75%.
| Gross Margin | 49.42% |
| Operating Margin | -154.13% |
| Pretax Margin | -182.41% |
| Profit Margin | -181.75% |
| EBITDA Margin | -167.59% |
| EBIT Margin | -154.13% |
| FCF Margin | -145.89% |
Dividends & Yields
LEGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.35% |
| FCF Yield | -6.44% |
Analyst Forecast
The average price target for LEGN is $86, which is 144.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $86 |
| Price Target Difference | 144.4% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 5.37 |
| Piotroski F-Score | 4 |